Repair of osteochondral defects : efficacy of a tissue-engineered hybrid implant containing both human MSC and human iPSC-cartilaginous particles
© 2023. Springer Nature Limited..
Both mesenchymal stromal cells (MSC) and induced pluripotent stem cells (iPSC) offer the potential for repair of damaged connective tissues. The use of hybrid implants containing both human MSC and iPSC was investigated to assess their combined potential to yield enhanced repair of osteochondral defects. Human iPSC-CP wrapped with tissue engineered constructs (TEC) containing human MSC attained secure defect filling with good integration to adjacent tissue in a rat osteochondral injury model. The presence of living MSC in the hybrid implants was required for effective biphasic osteochondral repair. Thus, the TEC component of such hybrid implants serves several critical functions including, adhesion to the defect site via the matrix and facilitation of the repair via live MSC, as well as enhanced angiogenesis and neovascularization. Based on these encouraging studies, such hybrid implants may offer an effective future intervention for repair of complex osteochondral defects.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
NPJ Regenerative medicine - 8(2023), 1 vom: 19. Okt., Seite 59 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Nakagawa, Shinichi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 22.11.2023 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1038/s41536-023-00335-x |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36350088X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36350088X | ||
| 003 | DE-627 | ||
| 005 | 20231226093501.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41536-023-00335-x |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1211.xml |
| 035 | |a (DE-627)NLM36350088X | ||
| 035 | |a (NLM)37857652 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Nakagawa, Shinichi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Repair of osteochondral defects |b efficacy of a tissue-engineered hybrid implant containing both human MSC and human iPSC-cartilaginous particles |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 22.11.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2023. Springer Nature Limited. | ||
| 520 | |a Both mesenchymal stromal cells (MSC) and induced pluripotent stem cells (iPSC) offer the potential for repair of damaged connective tissues. The use of hybrid implants containing both human MSC and iPSC was investigated to assess their combined potential to yield enhanced repair of osteochondral defects. Human iPSC-CP wrapped with tissue engineered constructs (TEC) containing human MSC attained secure defect filling with good integration to adjacent tissue in a rat osteochondral injury model. The presence of living MSC in the hybrid implants was required for effective biphasic osteochondral repair. Thus, the TEC component of such hybrid implants serves several critical functions including, adhesion to the defect site via the matrix and facilitation of the repair via live MSC, as well as enhanced angiogenesis and neovascularization. Based on these encouraging studies, such hybrid implants may offer an effective future intervention for repair of complex osteochondral defects | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Ando, Wataru |e verfasserin |4 aut | |
| 700 | 1 | |a Shimomura, Kazunori |e verfasserin |4 aut | |
| 700 | 1 | |a Hart, David A |e verfasserin |4 aut | |
| 700 | 1 | |a Hanai, Hiroto |e verfasserin |4 aut | |
| 700 | 1 | |a Jacob, George |e verfasserin |4 aut | |
| 700 | 1 | |a Chijimatsu, Ryota |e verfasserin |4 aut | |
| 700 | 1 | |a Yarimitu, Seido |e verfasserin |4 aut | |
| 700 | 1 | |a Fujie, Hiromichi |e verfasserin |4 aut | |
| 700 | 1 | |a Okada, Seiji |e verfasserin |4 aut | |
| 700 | 1 | |a Tsumaki, Noriyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Nakamura, Norimasa |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t NPJ Regenerative medicine |d 2016 |g 8(2023), 1 vom: 19. Okt., Seite 59 |w (DE-627)NLM269426779 |x 2057-3995 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2023 |g number:1 |g day:19 |g month:10 |g pages:59 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41536-023-00335-x |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2023 |e 1 |b 19 |c 10 |h 59 | ||